PMA supplement

P130017 S029: Cologuard Stool DNA-Based Colorectal Cancer Screening Test

FDA PMA supplement · Normal 180 Day Track · Exact Sciences Corporation

Key facts

Original PMA P130017
Supplement number S029
Supplement type Normal 180 Day Track
Reason for the supplement Labeling Change - Indications/instructions/shelf life/tradename
Trade name Cologuard Stool DNA-Based Colorectal Cancer Screening Test
Generic name System, colorectal neoplasia, DNA methylation and hemoglobin detection
Applicant Exact Sciences Corporation
Product code PHP
Received date Apr 12, 2019
Decision date Sep 20, 2019

At a glance

  • No Expedited review granted
  • No Approval order on file
  • No Summary of safety and effectiveness on file

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA supplements

A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA supplements